EMA Authorised: Leqvio (inclisiran) — Novartis Europharm Limited

View source ↗

Summary

The European Medicines Agency authorised Leqvio (inclisiran) from Novartis Europharm Limited for hypercholesterolemia and dyslipidemias, with the decision dated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemias
• Hypercholesterolemia

Drugs mentioned

• LEQVIO (inclisiran)

Snippet

Status: Authorised. Therapeutic area: Hypercholesterolemia;Dyslipidemias. MAH: Novartis Europharm Limited. Decision date: 04/03/2026